[1] N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China, 2019,” The New England journal of medicine, vol. 382, no. 8, pp. 727–733, 2020.
[2] World Health Organization. Coronavirus disease 2019 (COVID-19) situation report –52, https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn¼e2bfc9c0_4, Accessed 07 Jun 2020.
[3] World Health Organization. Coronavirus disease (COVID-19) outbreak situation, https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Accessed 28 Mar 2021.
[4] M. Phadke and S. Saunik, “COVID-19 treatment by repurposing drugs until the vaccine is in sight,” Drug development research, vol. 81, no. 5, pp. 541–543, 2020.
[5] S. E. Oliver, J. W. Gargano, M. Marin et al., “The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020,” MMWR. Morbidity and mortality weekly report, vol. 69, no. 50, pp.1922–1924, 2020.
[6] S. E. Oliver, J. W. Gargano, M. Marin et al., “The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020,” MMWR. Morbidity and mortality weekly report, vol. 69, no. 5152, pp.1653–1656, 2021.
[7] S. Torretta, G. Zuccotti, V. Cristofaro et al., “Diagnosis of SARS-CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature,” Ear, nose, & throat journal, vol. 100, 2_suppl, pp. 131S–138S, 2021.
[8] J. Adeoye and P. Thomson, “'The Double-Edged Sword' - An hypothesis for Covid-19-induced salivary biomarkers,” Medical hypotheses, vol. 143, 110124, 2020.
[9] R. Castro, P. M. Luz, M. D. Wakimoto et al., “COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil,” Brazilian journal of infectious diseases, vol. 24, no. 2, pp.180–187, 2020.
[10] Y. H. Jin, Q. Y. Zhan, Z. Y. Peng ZY et al., “Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version),” Military Medical Research, vol. 7, no. 1, 41, 2020.
[11] C. Danwang, F. T. Endomba, J. R. Nkeck et al., “A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19),” Biomarker research, vol. 8, 37, 2020.
[12] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[13] D. Trzybulska, E. Vergadi, and C. Tsatsanis, “miRNA and Other Non-Coding RNAs as Promising Diagnostic Markers,” EJIFCC, vol. 29, no. 3, pp. 221–226, 2018.
[14] B. R. Cullen, “Five questions about viruses and microRNAs,” PLoS pathogens, vol. 6, no. 2, e1000787, 2010.
[15] C. N. Correia, N. C. Nalpas, K. E. McLoughlin et al., “Circulating microRNAs as Potential Biomarkers of Infectious Disease,” Frontiers in immunology, vol. 8, 118, 2017.
[16] A. Guterres, C. H. de Azeredo Lima, R. L. Miranda, and M. R. Gadelha, “What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?,” Infection, genetics and evolution, vol. 85, 104417, 2020.
[17] R. Mirzaei, F. Mahdavi, F. Badrzadeh et al., “The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,” International immunopharmacology, vol. 90, 107204, 2021.
[18] F. Abedi, R. Rezaee, A. W. Hayes, S. Nasiripour, and G. Karimi, “MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents?,” Cell Cycle, vol. 20, no. 2, pp. 143–153, 2020.
[19] T. Abu-Izneid T, N. AlHajri, A. Mohammed Ibrahim et al., “Micro-RNAs in the regulation of immune response against SARS COV-2 and other viral infections,” Journal of advanced research, 2020. doi: 10.1016/j.jare.2020.11.013. Epub ahead of print.
[20] A. C. Tricco, E. Lillie, W. Zarin et al., “PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation,” Annals of internal medicine, vol. 169, no. 7, pp. 467–473, 2018.
[21] M. Ouzzani, H. Hammady, Z. Fedorowicz, and A. Elmagarmid, “Rayyan—a web and mobile app for systematic reviews,” Systematic reviews, vol. 5, no. 1, 210, 2016.
[22] W. R. Kim, E. G. Park, K. W. Kang et al., “Expression Analyses of MicroRNAs in Hamster Lung Tissues Infected by SARS-CoV-2,” Molecules and cells, vol. 43, no. 11, pp. 953–963, 2020.
[23] C. Li, X. Hu, L. Li, and J. H. Li, “Differential microRNA expression in the peripheral blood from human patients with COVID-19,” Journal of clinical laboratory analysis, vol. 34, no. 10, e23590, 2020.
[24] H. Tang, Y. Gao, Z. Li et al., “The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19”, Clinical and translational medicine, vol. 10, no. 6, e200, 2020.
[25] Y. M. Chen, Y. Zheng, Y. Yu et al., “Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage,” The EMBO journal, vol. 34, no. 24, e105896, 2020.
[26] H. Y. Zheng, M. Xu, C. X. Yang et al., “Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19,” Signal transduction and targeted therapy, vol. 5, no. 1, 294, 2020.
[27] J. Sabbatinelli, A. Giuliani, G. Matacchione et al., “Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients,” Mechanisms of ageing and development, vol. 193, 111413, 2021.
[28] A. Garg, B. Seeliger, A. A. Derda et al., “Circulating cardiovascular microRNAs in critically ill COVID-19 patients,” European journal of heart failure, 2021. doi: 10.1002/ejhf.2096. Epub ahead of print.
[29] C. E. Condrat, D. C. Thompson, M. G. Barbu MG et al, “miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis,” Cells, vol. 9, no. 2, 276, 2020.
[30] F. Coperchini, L. Chiovato, L. Croce, F. Magri, and M. Rotondi, “The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system,” Cytokine & growth factor reviews, vol. 53, pp. 25–32, 2020.
[31] M. Z. Tay, C. M. Poh, L. Rénia, P. A. MacAry, and L. F. P. Ng, “The trinity of COVID-19: immunity, inflammation and intervention,” Nature reviews. Immunology, vol. 20, no. 6, pp. 363–374, 2020.
[32] S. Fulzele, B. Sahay, I. Yusufu et al., “COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile,” Aging and disease, vol. 11, no. 3, pp. 509–522, 2020.
[33] G. Zhong, X. Cheng, H. Long et al., “Dynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma,” Journal of translational medicine, vol. 11, 71, 2013.
[34] J. D. Gagnon, R. Kageyama, H. M. Shehata et al., “miR-15/16 Restrain Memory T Cell Differentiation, Cell Cycle, and Survival,” Cell reports, vol. 28, no. 8, pp. 2169–2181, 2019.
[35] J. B. De Sanctis, A. García, J. Garmendia et al., “Importance of miRNA in SARS-CoV2 infection,” Gaceta médica de Caracas, vol. 128, Supl 1, pp. S1–S6, 2020.
[36] S. Y. Sung, C. H. Liao, H. P. Wu et al., “Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer”, PLoS One, vol. 8, no. 8, e71637, 2013.